Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994

被引：13

作者：

Gosse, ME

DiMasi, JA

Nelson, TF

机构：

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 1996年 / 60卷 / 06期

关键词：

D O I：

10.1016/S0009-9236(96)90209-X

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：608 / 618

页数：11

共 11 条

[1] BIOPHARMACEUTICALS AND CONVENTIONAL DRUGS - CLINICAL SUCCESS RATES [J].

BIENZTADMOR, B ;

DICERBO, PA ;

TADMOR, G ;

LASAGNA, L .

BIO-TECHNOLOGY, 1992, 10 (05) :521-525

[2]

BIENZTADMOR B, 1994, BIOPHARM-TECHNOL BUS, V7, P44

[3]

*BIO, 1995, ED REP GUID BIOT

[4]

CRAIG C, 1996, BIOWORLD TODAY, V7, P5

[5]

CRAIG C, 1996, BIOWORLD TODAY 0925, V7, P1

[6] NEW DRUG DEVELOPMENT IN THE UNITED-STATES FROM 1963 TO 1992 [J].

DIMASI, JA ;

SEIBRING, MA ;

LASAGNA, L .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (06) :609-622

[7] SUCCESS RATES FOR NEW DRUGS ENTERING CLINICAL-TESTING IN THE UNITED-STATES [J].

DIMASI, JA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :1-14

[8]

GOSSE ME, 1996, IN PRESS DIA J

[9] BIOPHARMACEUTICAL R-AND-D SUCCESS RATES AND DEVELOPMENT TIMES [J].

STRUCK, MM .

BIO-TECHNOLOGY, 1994, 12 (07) :674-677

[10]

VANBRUNT J, 1995, BIOWORLD FINANCIAL W, V3, P1

← 1 2 →